OXGENE introduces TESSA technology for robust, reproducible AAV manufacture at scale
OXGENE, a biotechnology company designing and developing scalable gene therapy technologies, has launched its scalable, plasmid-free manufacturing system for AAV. OXGENE’s new TESSA technology addresses industrywide challenges associated with robust and reproducible AAV manufacture at scale. These include high cost of goods and low packaging efficiency. TESSA aims to deliver a paradigm shift in scalable […]